Summary page of the EQA programme

Colorectal Carcinoma (CRC)

This page provides the information about the programme in a nutshell. It is as concise as it can be.

Programme description

The programme is focused on external quality assessment of testing of mutations of clinically most important genes relevant to anti-EGFR therapy in colorectal carcinoma - KRAS, NRAS, BRAF. Participants are expected to identify and describe mutations, they can choose any combination of KRAS, NRAS, BRAF testing.
Complete description you can find in the EQA Plan 2024 (namely page 30).
Short description is available in the CRC 2024 flyer.

Professional supervision

ESP European Society of Pathology Quality Assurance Foundation
Barastraat 6, 1070 Brussels, Belgium

EQA provider

SEKK s.r.o., EHK Division
ArnoŇ°ta z Pardubic 2605, 530 02 Pardubice, Czech Republic
Accreditation: Certificate of accreditation

Participation in the year 2024

The laboratories from all countries are welcome to participate in CRC programme.

Very simple guide on how to order the Colorectal Carcinoma (CRC) and Programmed Death Ligand 1 (PDL1) programmes is available here.

Results and evaluation

We believe that these examples will give you a good insight.

Public part of the evaluation
(EQA round CRC1/23)
Private part of the evaluation
(anonymised and shortened examples from the EQA round CRC1/23)
Final report
Final report
Summary statistics
Summary statistics
Confirmation of attendance
Confirmation of attendance
CertificateCertificate Result sheetResult sheet

To view the latest finished EQA round (CRC2/23) please click here.

Last update: 13.10.2023